First results on the chemical composition profile Gardasil 9

First results on the chemical composition profile Gardasil 9

We arrive with this analysis to the fourth vaccine analyzed with this method, which aims to determine the chemical-protein composition of the analyzed vials.

On this occasion we focused on a vaccine that is not mandatory in Italy, the one against papilloma virus, but that has made much discussion in the recent past for the numerous reports of suspected adverse reactions received over time. The HPV vaccines have made much discussion, even outside Italy; hence the decision to dedicate our attention also to this product.

ATTENTION: Gardasil 9 is an anti-Hpv vaccine which should contain, from package leaflet, 9 antigens, for 9 different subtypes of the Hpv virus (subtype 6 -11 - 16 - 18 - 31 - 33 - 45 - 52 - 58). However, not all the antigens that are declared have been detected, but only 7 out of 9.

With reference to the method, the disputes and technical criticisms made in recent weeks, we replied (link report https://goo.gl/WfRBJB) with the final analysis report. We suggest reading and spreading this document, together with the rest, because the explanations are rather detailed and precise.


In this sample of Gardasil 9 the following were found, as for the previous vaccines analyzed:

  • Chemical contaminations from the manufacturing process or from cross-contamination with other production lines
  • Chemical toxins

ANTIGENS: as anticipated, Gardasil 9 is an anti-Hpv vaccine that should contain, from package leaflet, 9 antigens, for 9 different subtypes of the Hpv virus (subtype 6 -11 - 16 - 18 - 31 - 33 - 45 - 52 - 58 ). Of these, the following were NOT detected:

  • Human Papillomavirus Type 1 L11 Protein (one of the subtypes most commonly associated with cervical lesions)
  • Human Papillomavirus Type 1 L58 protein (one of the subtypes most frequently associated with cervical cancer)

These two subtypes were not detected with the method in use (unlike the remaining 7).


Again, therefore, we are faced with a product that does NOT seem to contain what it should contain. That is, of 9 antigens, only 7 were detected.
This opens up an important question about product compliance. A question that is not for us to resolve, and that as always we turn to those in charge.

In addition to that, they have been encountered 338 signals of chemical contaminants of which 22% are known. This data is also in continuity with the previous ones.
Among these signals, 10 chemical toxins have also been identified, probably coming from the antigen processing process or from other production processes present at the vaccine production site.

In conclusion, even Gardasil9 - as well as the hexavalent Hexyon and Infanrix hexa as well as the quadrivalent Priorix Tetra - according to the method we commissioned, leaves enormous doubts both on efficacy and safety.

These products, like any other pharmaceutical product, have undesirable effects and can trigger adverse reactions of various magnitudes, even serious ones. If the efficacy is questioned by the lack of one or more antigens compared to what is declared by the manufacturer, this must be a fact known to those who undergo their administration (otherwise it would be a fraudulent behavior by those who sell it and who administers it); for this reason it is of fundamental importance to continue scientific research on the content of vaccines, in consideration of the fact that the pediatric population is the main recipient, that the subjects to whom they are administered do not suffer from any manifest pathology, and that there is an indication of the need for preventive prophylaxis through these products by the institutions, which are therefore directly involved in the evaluation of their safety profile and their compliance.


Download: CORVELVA-Report-analysis-composition-chemical-Gardasil9.pdf